Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Sam Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero (2025). Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7513.
